Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings
Rhea-AI Filing Summary
Scribe Therapeutics, Inc. insider Brett Staahl, reported as a ten percent owner, filed an initial statement of beneficial ownership. He holds 524,336 shares of Common Stock directly. In addition, he reports four stock option awards over Common Stock with exercise prices of $3.08, $6.40 and $19.13, covering 2,462, 17,798, 4,755 and 1,688 underlying shares, expiring between 2030 and 2036. Certain options are fully vested, while one grant began vesting 25% on January 1, 2026 with the remainder vesting in equal monthly installments subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Staahl Brett
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 26,703 shares (Direct);
Common Stock — 524,336 shares (Direct)
Footnotes (2)
- F1. The option is fully vested.
- F2. The options vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Key Figures
Common Stock held: 524,336 shares
Option exercise price: $3.08 per share
Option exercise price: $6.40 per share
+3 more
6 metrics
Common Stock held
524,336 shares
Directly owned Common Stock reported by Brett Staahl
Option exercise price
$3.08 per share
Stock Option (Right to Buy) over 2,462 underlying Common shares, expiring 2030-06-07
Option exercise price
$6.40 per share
Stock Option over 17,798 underlying Common shares, expiring 2031-08-05
Option exercise price
$19.13 per share
Stock Option over 4,755 underlying Common shares, expiring 2036-03-12
Partially vesting option
1,688 underlying shares
Stock Option at $6.40 expiring 2035-03-20 with staged vesting from January 1, 2026
Ten percent owner status
Yes
Reporting person classified as ten percent owner of Scribe Therapeutics
Key Terms
Stock Option (Right to Buy), underlying security, vested, beneficial ownership
4 terms
Stock Option (Right to Buy) financial
"He reports four Stock Option (Right to Buy) positions over Common Stock"
underlying security financial
"each option lists an underlying security title of Common Stock"
vested financial
"The option is fully vested and another grant vested 25% on January 1, 2026"
beneficial ownership financial
"filed an initial statement of beneficial ownership as a ten percent owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What does the Form 3 filing for SCTX by Brett Staahl disclose?
The Form 3 shows that Brett Staahl, a ten percent owner of Scribe Therapeutics (SCTX), holds 524,336 common shares directly plus several stock option awards over additional common shares with varying exercise prices and expirations.
What stock options over Scribe Therapeutics (SCTX) does Brett Staahl report?
He reports four Stock Option (Right to Buy) positions over SCTX Common Stock, covering 2,462, 17,798, 4,755 and 1,688 underlying shares, with exercise prices of $3.08, $6.40 and $19.13, expiring between 2030 and 2036.
Are any of Brett Staahl’s Scribe Therapeutics (SCTX) options fully vested?
Yes. A footnote states that certain options are fully vested. Another grant vested 25% on January 1, 2026, with the remaining 75% vesting in equal monthly installments, subject to continued service to Scribe Therapeutics.
Does the SCTX Form 3 show recent buy or sell transactions by Brett Staahl?
No buy or sell transactions are indicated. The entries are reported as holdings, listing existing Common Stock and stock option positions, rather than new purchases, sales, or exercises on the transaction date.
Why is Brett Staahl classified as a ten percent owner of Scribe Therapeutics (SCTX)?
The Form 3 designates him as a ten percent owner, meaning his reported beneficial holdings meet the SEC threshold for that status, which requires initial reporting of his Scribe Therapeutics equity positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
